Six-Gene Signature in Hidden Liver Micrometastases May Predict Colorectal Cancer Recurrence Risk
核心洞察
Researchers at MD Anderson identified a six-gene signature in microscopic colorectal cancer (搜索) liver metastases linked to minimal residual disease (搜索), recurrence risk, and chemotherapy resistance.
The MicroMetSig-high signature was associated with shorter disease-free and MRD-free survival across multiple patient datasets, suggesting potential as a tissue-based prognostic marker.
Spatial mapping revealed micrometastases are surrounded by exhausted immune cells and express PD-1/PD-L1 (搜索) immune-suppressing signals, pointing to possible therapeutic targets.
Researchers at The University of Texas MD Anderson Cancer Center have identified a six-gene signature in microscopic colorectal cancer (搜索) (CRC) liver metastases that may help predict which patients face a higher risk of recurrence after treatment. Published in Cancer Cell, the study used advanced spatial genomic technologies to reveal how these tiny, often undetectable tumor deposits — known as micrometastases — evolve, evade the immune system, and persist after surgery or chemotherapy.
The research was co-led by Dipen Maru, M.D., professor of Anatomical Pathology; Scott Kopetz, M.D., Ph.D., professor of Gastrointestinal Medical Oncology and associate vice president for Translational Integration; and Linghua Wang, M.D., Ph.D., professor of Genomic Medicine and executive director of the Center for Cellular Language Intelligence, together with co-first authors Yang Liu, Ph.D., and Akshaya Jadhav, M.D.
“These findings provide critical insights into how colorectal cancer (搜索) cells can hide after treatment and later return, suggesting that tissue-based markers could complement blood-based tests to help identify patients at higher risk of recurrence,” Maru said. “While this gene signature needs validation in larger cohorts to establish clinical efficacy, we are encouraged by the translational relevance of these results.”
The Biology of Hidden Metastases
Colorectal cancer (搜索) can recur when small numbers of cancer cells remain after surgery or chemotherapy — a state known as minimal residual disease (搜索) (MRD). These residual cells may shed circulating tumor DNA (ctDNA) into the bloodstream but often remain invisible on routine imaging. While ctDNA-based liquid biopsies can detect signs of MRD, they cannot reveal where residual cancer cells reside or how they survive treatment.
The MD Anderson team examined 49 tumors from 19 patients with primary CRC and matched liver and lung metastases. They discovered that liver micrometastases appeared early in tumor evolution and displayed dormant, stem-like features that may allow these microscopic clusters to withstand therapeutic assault.
A Six-Gene Signature with Prognostic Power
Using high-resolution spatial profiling, the researchers compared gene activity in liver micrometastases, larger macrometastases, and adjacent noncancerous liver tissue. This analysis narrowed to six genes that marked a distinct micrometastatic tumor cell state. Higher expression of this signature — termed MicroMetSig-high — was associated with shorter disease-free survival, shorter MRD-free survival, and increased risk of recurrence and chemotherapy resistance across several independent patient datasets.
“Micrometastases are not simply smaller versions of macrometastases, but rather they appear to represent a distinct biological state,” Wang said. “Using spatial multi-omics and computational analysis, we were able to compare microscopic and larger metastases directly in tissue to help identify programs linked with tumor persistence and disease recurrence.”
Immune Evasion Mechanisms
Spatial mapping revealed that liver micrometastases were frequently surrounded by immune cells, yet many of those cells displayed signs of exhaustion, indicating weakened antitumor activity. The micrometastases also exhibited immune-suppressing signals involving PD-1/PD-L1 (搜索) and other immune checkpoint pathways. These findings suggest that targeting these pathways could represent a future therapeutic strategy to reduce recurrence risk.
The researchers emphasized the need for functional studies to define precisely how micrometastases suppress immune responses and survive treatment, which could lead to approaches that eliminate dormant cancer cells before they trigger recurrence.
Complementary Evidence from Blood-Based MRD Testing
In a separate study presented at the ESMO Gastrointestinal Cancers Congress 2026, the Phase II GALAXY study — led by researchers from Hyogo Medical University in Japan with collaborators including the University of Oxford — evaluated ctDNA testing in 298 patients who underwent surgery for colorectal cancer (搜索) that had spread to the liver. Blood samples were collected between two and ten weeks after surgery using a personalized ctDNA test.
Among patients who had surgery first, those with detectable ctDNA had significantly worse outcomes. Critically, ctDNA-positive patients who received adjuvant chemotherapy achieved a four-year overall survival rate of 65%, compared with just 33% for those who did not receive chemotherapy. Disease-free survival was also substantially higher in the treated group. Patients with negative ctDNA tests had favorable outcomes regardless of whether they received chemotherapy, suggesting that some individuals may safely avoid unnecessary treatment.
In patients who had already received chemotherapy before surgery, ctDNA status still predicted recurrence risk, but additional chemotherapy after surgery did not appear to improve survival.
Toward Personalized Recurrence Monitoring
The MD Anderson findings may help bridge the gap between blood-based MRD testing and the tissue biology that drives relapse. If validated in larger cohorts, the six-gene signature could be developed into a clinical tool to identify patients who need closer monitoring or additional treatment after surgery. The GALAXY study results similarly point toward a future where ctDNA-guided treatment decisions spare low-risk patients from unnecessary chemotherapy while ensuring high-risk patients receive the intervention they need.
Both research groups caution that larger randomized clinical trials are required before these approaches can be integrated into routine clinical practice.